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Abstract
Even though controversies surrounding the polycystic ovary syndrome are not yet 
close to be solved, its clinical manifestations are well known—insulin resistance and 
obesity, hirsutism, irregular and anovulatory menstrual cycles. The treatment of 
polycystic ovarian syndrome (PCOS) is mainly symptomatic as its etiology is not yet 
clear. Lifestyle changes are the primary therapy in overweight and obese women with 
PCOS. According  to majority  of  the  studies,  lifestyle  changes  are  the most  effective 
form of treatment not only for weight loss but also for the improvement of insulin sen-
sitivity, decreasing incidence of metabolic syndrome and type 2 diabetes. Studies also 
show that weight loss has fertility benefits by restoring ovulatory cycles. Although ini-
tial studies researching pharmacologic treatment were showing excellent results con-
cerning the weight loss, maintenance of weight loss and reduction of cardiovascular 
risks, some of these drugs were in the end, has proven to actually increase the risk for 
cardiovascular events and were removed from the market. Bariatric surgery has been 
demonstrated to improve or even cure type 2 diabetes, hypertension, hyperlipidemia, 
and obstructive sleep apnea. More so, there are studies that reported complete reso-
lution of all features of PCOS, even hirsutism, hyperandrogenism, anovulation, and 
menstrual irregularity.
Keywords: polycystic ovarian syndrome (PCOS), obesity, hyperandrogenism, 
anovulation, hirsutism, metabolic syndrome, weight loss
1. Introduction
Polycystic ovary syndrome (PCOS) is considered to be the most common endocrinopathy 
affecting women with an incidence ranging from 5 to 13% [1], depending on the diagnostic 
criteria applied.
© 2018 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
Polycystic ovary syndrome—in spite of many years of research—is still a controversial topic. 
We have come to know in detail its clinical manifestations such as metabolic disorders, men-
strual and ovulatory dysfunctions, and clinical hyperandrogenism. However, not knowing 
its etiology, most of the treatments suggested to patients with PCOS are symptomatic, not 
addressing to the underlying cause, but rather each symptom in part.
Following numerous studies and research on PCOS and despite that the exact mechanism is 
not completely understood, the conclusions of most researchers are the same; lifestyle change 
and weight loss have beneficial effects on the entire panel of symptoms associated with this 
syndrome.
2. Which are the main goals when treating PCOS?
2.1. Management of underlying metabolic disorders, reduction of risk factors for 
type 2 diabetes and cardiovascular disease
2.1.1. Obesity
Under the metabolic disorders, which are commonly encountered in patients with PCOS, it 
is worth mentioning: obesity, insulin resistance, metabolic syndrome, dyslipidemia, and type 
2 diabetes mellitus.
Some researchers state that the obesity rate in the case of the women with PCOS is even 
up to 70%, but most agree that at  least half of the women with PCOS suffer from obesity 
(body mass index (BMI) = 19–25 kg/m2) [2] and in most cases, it is of a central distribution 
(waist circumference > 88 cm) [3]. Of the nonobese patients, one-third has increased intra-
abdominal fat [4]. There is no specific data on why the prevalence of obesity is much higher 
in women with PCOS, but most researchers attribute  it  to  the hyperinsulinemia resulting 
from the insulin resistance, an important factor of adipogenesis, lipogenesis, and lipolysis 
inhibition [5].
2.1.2. Increased insulin resistance
Insulin resistance and reactive hyperinsulinemia are definitely implicated in the physiopatho-
logical mechanism of PCOS. With respect to insulin resistance, some authors consider it to be 





The metabolic syndrome is commonly associated with PCOS, with a prevalence ranging 
between 33 and 47% [9]. Both PCOS and the metabolic syndrome have features that generate 
an increased risk of cardiovascular diseases–if this risk is independent of PCOS or it is caused 
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by its association with the metabolic syndrome, it is still a topic of debate [10]. Studies demon-
strate that in patients with PCOS, even if the criteria for the metabolic syndrome are not fully 
met, there is at least one component of the metabolic syndrome [11].
The research in the field demonstrates the presence of the risk factors for the metabolic syn-
drome in women with PCOS. Of these, the following appear to be important: the level of fast-
ing insulin (which in these patients is doubled [12]) and obesity (an independent risk factor 
for the metabolic syndrome).
2.1.4. Impaired glucose tolerance or type 2 diabetes mellitus
Impaired glucose tolerance (IGT) or even type 2 diabetes mellitus (T2DM) are common in 
patients with PCOS with  a  prevalence  rate  of  30–40%  for  impaired  glucose  tolerance  and 
7.5–10% for type 2 diabetes mellitus [13, 14]. The risk of patients with PCOS to develop these 





It is not known exactly to what extent PCOS would be an independent risk factor for car-
diovascular diseases but, unquestionably, through associated pathologies (obesity, increased 
resistance to insulin, IGT, T2DM, and/or dyslipidemia), it contributes to an increased risk [15].
2.2. Improvement of hyperandrogenic symptoms (hirsutism, acne, scalp hair loss)
Most  experts  consider  that  hyperandrogenism  is  the  main  characteristic  of  PCOS  [16], 
whether is biochemically or clinically identified. Alteration in insulin action as well as enzy-
matic defaults has been discussed as possible pathogenic theories.
Studies  suggest  that  the  androgenic  hyper-responsiveness  that  characterizes  women  with 
PCOS  is  probably  due  to  the  factors  controlled  by  insulin  sensitization  rather  than  lutein-
izing hormone  (LH),  adrenocorticotropin hormone  (ACTH),  or ovarian  steroids per se  [16]. 
Multiple molecular and cellular pathways seem to be involved in the production of androgenic 
hormones, most of  them  involving ovarian  theca  cells,  insulin  receptors, Cytochrome P450 
17α-monooxygenase  (P450c17) activity as well as  components of mitogen-activated protein 
kinase (MAPK) insulin pathway.
The clinical correspondence of this intricate biochemical processes have incredible impact 




obese tend to have higher hirsutism and acne scores than their  lean counterparts [16]. The 
consequent importance of weight loss is therefore essential to be taken into account. It is 




insulin  levels  [17].  Lifestyle modifications  reside  once  again  as  the  first  step  therapeutical 
management in patients with PCOS.
2.3. Prevention of endometrial hyperplasia
The  modified  metabolic  background  associated  with  PCOS  is  basically  characterized  by 




mately 30% of women with PCOS fail to respond to such treatment [20] and progress to the 
development of atypical hyperplasia and further transformation to endometrial cancer [21].
The mechanism of progesterone resistance is determined at molecular level and based on the 
imbalance of two progesterone receptor (PR) isoforms PRA and PRB. Patients with PCOS 
have a modified ratio of PRA to PRB receptors present on stromal and epithelial cells of endo-
metrium [21].
Progesterone  resistance  is associated with  insulin  resistance  [20] and this way, a new per-
spective in the prevention of endometrial hyperplasia can be contoured: targeted therapy on 
reducing insulin resistance may benefit both endometrial tissue and serum hyperinsulinemia.
2.4. Voluntary contraception for patients
Although most of PCOS-diagnosed patients complain about the inability to pursue a preg-
nancy, it is important to have in mind the situation when women diagnosed and treated for 
PCOS do not want to obtain a pregnancy.
A recent study states that in women aged 28–33 years old, women with PCOS were less likely 
to be using contraception (61 versus 79%, P < 0.001) and more likely to be trying to conceive (56 
versus 45%, P < 0.001), compared with women not reporting PCOS [22]. However, the same 
study mentions that fewer women with PCOS (61%) were using contraception than women 
without PCOS (79%) (P = 0.001) [22].
Because women with oligomenorrhea ovulate  intermittently and  rarely use  contraception-
unwanted pregnancy may occur.
2.5. Induced ovulation for patients pursuing pregnancy
As part of the PCOS, infertility secondary to anovulation is usually the main complaint of 
patients diagnosed with this metabolic disorder.
Pathological basis of infertility in this particular medical situation resides in the low Follicle-
stimulating hormone (FSH) serum level, which is responsible for the impossibility of ovarian 
follicles to reach maturity due to their persistence in final growth stages.
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Aiming to treat this frequent cause of anovulation, there are two ways to ensure the wellbeing 
of the patient based on each woman’s choice: evaluating the options for further contraception 
or starting a therapeutical plan for inducing ovulation.
With respect to the latter, inducing ovulation still remains a medical challenge in some patients 
with PCOS. There are a few known therapeutical approaches for achieving this: medical treat-
ment with clomiphene citrate, tamoxifen, aromatase inhibitors, metformin, glucocorticoids, or 
gonadotropins or surgically management by laparoscopic ovarian drilling [23]; in vitro fertil-
ization is also taken into consideration when all the other options failed to induce pregnancy.
3. Why are lifestyle changes and weight loss important in women 
with PCOS?




cardiovascular disease or endometrial hyperplasia. Moreover, there are studies that discuss 




others involved in a series of controversies.
3.1. Metabolic profile
An improved lifestyle will undoubtedly improve the distribution of the adipose tissue and 
will in most cases lead to weight loss. A weight loss of between 5 and 10% will ameliorate IGT 
and will decrease the prevalence of the metabolic syndrome and diabetes mellitus [25].
Research suggests that these interventions are associated with lower fasting insulin levels and 








During  the  treatment,  we  also  seek  to  improve  the  hormonal  profile  since  PCOS  being  a 
pathology with deep hormonal implications. Unanimously, studies describe a decrease in the 
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total  testosterone  level  [28] and in androstenedione [29] as a result of lifestyle changes and 
weight loss. There is, however, controversy in terms of improving the level of SHBG and free 
androgen  index  (FAI)  [29]. However, in all cases, an improvement in hirsutism will result 
when using the Ferriman-Gallwey (FG) score as an objective measuring method.
While the level of FSH increases as a result of lifestyle changes and weight loss, more by 
means  of  physical  exercise  than  a  result  of  diet  [29], the level of LH does not seem to be 
improved by following a hygienic-dietary diet.
3.3. Reproductive potential
In PCOS treatment, we aim to restore both normal menstrual function and fertility. In some 
cases, there may also be a decrease in ovarian volume and a reduction in the number of follicles 
[30] following weight loss and lifestyle changes. Ovulatory menstrual cycles can be obtained for 




4. What lifestyle changes should be adopted for women with PCOS?
Although the last decades have been revolutionary in terms of understanding this pathology, 
its etiology is not elucidated, hence we cannot talk about the existence of a curative treatment, 
but rather of symptomatic  treatments. The spectacular evolution  in  this field also refers  to 
the many symptomatic treatments, whose efficiency, although relatively high, address each 
symptom in part and not the pathology as a whole. The change in lifestyle, with all the devel-
opments in the last decades, still seems the most approachable and most effective treatment 
method, at the same time covering a broad spectrum of symptoms.
When we talk about lifestyle changes, we refer to a healthy lifestyle that involves exercise 
and weight loss. Although in many cases, patients are able to lose weight and lead a healthy 
lifestyle for a while, the difficulty they encounter is to maintain this lifestyle and their weight 
in the long run.
A solution to this problem is the behavioral treatment by “Burtyn and co.” designed specifi-
cally  to help with this–a complex program that not only helps patients  to  lose weight effi-
ciently but also to maintain their weight in the long term or even continue to lose more over 
time. Patients undergo this program for a period of 4–6 months under the supervision of a 
group of specialists: nutritionists and psychologists [33]. Patients learn how to choose healthy 
foods, how to ration their portions and how to get social support. After setting objective tar-
gets in terms of daily caloric intake, time spent on physical exercise and other behavioral 
changes, patients share in weekly or bi-weekly group sessions the obtained results. Specialists 
recommend patients to expect a weight loss of 0.5–1 kg per week, mentioning that the final 
target is a 10% decrease in weight relative to their initial weight [33]. They argue that by a 
comprehensive behavioral approach, patients manage to decrease 8–10 kilograms in weight 
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and that about 80% of patients starting this program manage to complete it [34]. However, 
specialists mention that in the absence of weight maintenance therapy, regaining weight will 
be inevitable.
The National Institute of Health also recommends psychotherapeutic and social support for 
these patients in order to manage to maintain their weight in the long run or even to further 
lose weight.
4.1. What diets do we choose in order to lose weight?
Regarding the type of diet, there are no clinically relevant data to prove the efficacy of any 
of them in the case of patients suffering from PCOS. However, based on food principles and 
taking into account that a decrease in carbohydrate intake would lead to a decrease in hyper-
insulinemia, which in turn would lower insulin resistance, low-carbohydrate diets would be 
favored. Nevertheless,  a  comparative  study between a high protein/low carbohydrate diet 
(40% carbohydrate, 30% protein, and 30% fat) and a low protein/high carbohydrate diet (55% 




and reproductive improvements [26]. A meta-analysis of 48 clinical trials involving a total of 
2886 patients concludes that regardless of the type of diet and macronutrient on which they 
are based, there will be a relatively comparative weight loss–the same thing happening with 
maintaining weights at follow-up for 6 months and 12 months [35]. The impact of the type of 
macronutrients used in the diet is still debated. What is certain is that less energy intake than 
energy consumption will result in a weight loss. Thus, high-level metabolic studies conclude 
that a caloric intake of less than 1000 kcal/day will show results in all cases, with no exception.
New diet hypothesis have emerged over the last few years, and here we want to mention 
the fast-paced ones, which are still under investigation and seem to be ground-breaking. 
Researchers  believe  that  patients  with  PCOS might  have  significant  benefits  in  terms  of 
PCOS symptoms but also complications in the medium to long term if approaching this 
type of diets. The data we currently have on  intermittent  fasting diet obtained on rodent 
models are promising in terms of results. Thus,  intermittent fasting diets, as compared to 
diets based on energy restriction of continued iso-energetic type, improve insulin sensitivity 
[36], provide protection for the cardiovascular system [37], and increase the lifespan of the 
rodent in the model. [38] Moreover, 3 days or more of the fasting will result in at least a 30% 
decrease in circulating insulin levels, glucose levels, and insulin-like growth factor 1 (IGF-1), 
which plays a key role in the metabolic homeostasis and changes associated with aging 
[39]. Current theories take into account the possibility that this type of diet can improve 
the symptoms of hyperandrogenism, based on the argument that improving insulin resis-
tance would reduce compensatory hyperinsulinemia and ultimately the excess of androgen 
involved in the PCOS symptomatology.
Finally, we want to emphasize the importance of weight loss, pointing out the uselessness of 
this fact if the patients fail to maintain their long-term weight.
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4.2. What is the importance of physical exercise?
Physical exercise is definitely a part of the lifestyle changes. Studies show that the type, fre-
quency or duration of  the exercise do not  influence  the  results  that patients get  from  it.  It 
has been shown that regular, aerobic exercise of moderate intensity does not only contribute 
to weight loss and improved insulin resistance, but also improves reproductive outcomes, 
including ovulation and regulation of menstrual cycles. The recommendation for patients 
with PCOS in view of the improve reproductive and cardio metabolic outcomes is – aerobic 
physical activity of moderate intensity for 90 minutes per week [40].
5. What methods do we choose in order to obtain weight loss?
5.1. Pharmacological treatment for obesity
In a relatively recent past, following multiple clinical trials, medical journals supported the 
benefit of adding anti-obesity drugs to lifestyle changes–both in terms of maintaining weight 
in the long-term and reducing associated co-morbidities. Drugs such as sibutramine, orlistat, 
and  rimonabant  have  been  shown  to  be  effective  in  improving  the  lipid  profile,  lowering 
blood pressure, glycosylated hemoglobin (in diabetics), and pro-inflammatory cytokine lev-




mate, bupropion naltrexone, liraglutide and noradrenergic sympathomimetic drugs but there 
are no specific studies with patients suffering from PCOS. A list of medication used to treat 
obesity is shown in Table 1.
5.1.1. Drugs that alter fat digestion
Orlistat, being an inhibitor of pancreatic and gastric lipases, inhibits the hydrolysis of triglyc-
erides from the diet by up to 30%, thus reducing total caloric intake [41]. Hence, weight loss 
is not  significant using  this medication only and  requires a  calorie-restricted  regimen. The 
X-PERT study establishes a 3-month weight loss that exceeds 5% of the initial weight as an 
accurate predictor of long-term weight loss. A 12-month meta-analysis concludes that patients 
undergoing lifestyle changes that also associate orlistat as an adjuvant medication will lose an 
average of 8–10 kg over 12 months as opposed to those who associate lifestyle change with 
a placebo who will lose an average of 3–6 kg [43]. In addition to weight loss, it has positive 
effects in reducing cardiovascular risk factors due to its effects on triglyceride and LDL cho-
lesterol [41]. Moreover, in Orlistat treatment, a better glycemic control with decreasing fasting 
glucose and glycosylated hemoglobin is noticed [44]. This is considered to be a relatively safe 
drug, with adverse effects mainly upon the intestinal tract such as increased defecation, fatty 
stools, and fecal urgency.
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5.1.2. Serotonin agonists
Lorcaserin  is  believed  to  activate  serotonin  5-HT2c  receptors  stimulating pro-opiomelano-
cortin (POMC) neurons in the arcuate nucleus of the hypothalamus. Thus, it increases alpha-
melanocortin stimulating hormone resulting in satiety and consequently in a decreased food 
intake [45]. Lorcaserin is indicated for the treatment of obesity when it is associated with at 
least one comorbidity such as type 2 diabetes mellitus, high blood pressure, high cholesterol 
or sleep apnea [46]. This is an alternative to orlistat, with similar efficacy but fewer side effects. 
In addition to weight loss, studies show that it lowers: blood pressure, heart rate, total choles-
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cardiovascular system were those that caused the withdrawal of some drugs of this class from 
the market, such as sibutramine (removed from the market in 2010 [47] after it was shown to 
increase the risk of myocardial infarction and stroke [48]) or phenylpropanolamine (removed 
from the market due to association with increased risk of hemorrhagic stroke in women [49]).
5.1.4. Antidepressants and antiepileptic drugs
Antidepressants and antiepileptics can affect weight  in different ways, while some  lead  to 
weight gain, others to loss. Among the drugs that lead to weight loss, we mention: bupropion, 
venlafaxine, desvenlafaxine, topiramate, zonisamide, lamotrigine, and ziprasidone [45].
Bupropion is an antidepressant commonly used in cases of smoking cessation, to prevent 
weight gain [50]. It can also be used in combination with naltrexone, although there are cur-
rently no data on an augmenting the effect of bupropion by naltrexone.
Topiramate is an antiepileptic agent that blocks neuronal voltage-dependent sodium chan-
nels, enhances gamma-aminobutyric acid (GABA) A activity and inhibits carbonic anhydrase, 
generating  appetite  suppression  and  satiety  enhancement. Amongs  its  adverse  effects, we 
mention paresthesia, somnolence, and metabolic acidosis. Studies recommend its use in com-
binations with other substances and not as a sole agent in the treatment of obesity.




Metformin is an anti-hyperglycemic biguanide, used in the treatment of type 2 diabetes mel-
litus. It reduces liver production and intestinal absorption of glucose and therefore insu-
lin  secretion. By  its anti-lipolytic  effect,  free  fatty acid concentrations and gluconeogenesis 
decrease  [52, 53]. Numerous studies have been performed on obese patients with PCOS, 
who received metformin. While the first studies seemed to demonstrate its effects in terms 




oligomenorrhea or weight loss.
Pramlintide is a synthetic analog of human amylin whose effect in terms of weight loss is rela-
tively modest, due to its slowing effect on gastric emptying and the reduction in postprandial 
blood glucose concentration it causes.
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even orlistat when administered  in high doses  [55]. Among  its adverse effects when admin-
istered at high doses are included nausea and vomiting, which may in part contribute to the 
weight-loss effect [55]. This drug is quite often avoided due to its route of administration (subcu-
taneous injection) but also due to its potential adverse effects, that although rare, they are severe 
(pancreatitis, renal impairment and gallbladder disease). Further, we consider important to 
mention that rodent studies have demonstrated the association of this drug with the increased 
frequency of thyroid C-cell tumors (benign and malignant), which is why it is not recommended 
in the case of the patients with personal or family history of medullary thyroid cancers [56].
5.1.6. Combination drugs
The combination of phentermine and topiramate is another two drug combination with 
good effect  in  terms of weight  loss, being pharmacologically  included  in  the sympathomi-
metic anorexia class. Being a two drug combination, it has a complex mechanism of action. 
Thus, phentermine, which is a sympathomimetic amine, like amphetamines, will reduce the 
appetite after the stimulation of the hypothalamus and the release of the norepinephrine. 
Topiramate also has appetite suppressing effects and causes rapid satiety. Studies show that 
after a 1-year administration, the effect of this combination drug on weight loss decreases, but 





tered it would fail in addressing the underlying reason for initiating this therapy.
5.2. Surgical treatment of obesity–bariatric surgery
Bariatric surgery is indicated in cases of morbid obesity (BMI = 40 kg/m2 or BMI greater than or 
equal to 35 kg/m2 associated with different comorbidities). A study that enrolled obese patients 
who underwent bariatric surgery divided the treated patients into 3 groups; obese with PCOS, 
obese with hyperandrogenemia characteristics but with regular menstrual cycles and a third 
group with obese patients without hyperandrogenic traits. After applying the exclusion criteria, 
the group of patients with PCOS was studied in detail and the results were surprising. Within 
12 +/− 5 months, the weight loss was of 41 +/− 9 kg, associated with the improvement of clinical 
and biochemical markers of hyperandrogenism. It was noted that an improvement in hirsutism 
had been observed and from a biochemical point of view markers such as: free testosterone, 
total testosterone, androstenedione and dehydroepiandrostenedione sulfate have been normal-
ized while the level of SHBG increased. From a metabolic point of view, the improved insulin 
sensitivity was proved by the decrease in fasting insulin levels. With regard to the reproductive 
system, the restoration of regular menstrual cycles and ovulation were noticed [60].
A newer study, conducted in 2012, concludes that weight loss after bariatric surgery is not 
associated with  significant  changes  in  the menstrual  cycle,  the  luteal  phase  length  or  the 
amount of blood lost during menstruation. A relatively modest improvement was found 
with  respect  to biochemical hyperandrogenism but without  effects on  the  clinical markers 
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We consider to be of major importance the adoption of a healthy lifestyle, composed of a hypo 
caloric diet and physical exercise that will generate weight loss. Unlike any other treatment, 
weight loss without adjuvant medication (which brings various side effects) in many cases 
leads to at least partial resolution of PCOS symptoms. Although in this chapter by enlarge we 
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